Sphere Bio joins MabDesign: accelerating biotherapeutic innovation together
As the newest international member of MabDesign, we’re expanding our reach across Europe and supporting the future of biologics development.
Cambridge, UK [20 March, 2025]: We’re proud to announce that Sphere Bio has joined MabDesign, the leading French network supporting innovation in biotherapies and biomanufacturing.
As a pioneer in picodroplet microfluidics, our mission is to help scientists around the world find, select, and scale the rare cells that lead to life-changing therapies. From antibody discovery to cell therapy and cell line development, our Cyto-Mine® platform empowers researchers to screen millions of single cells with speed, precision, and monoclonality assurance—helping ideas reach the clinic faster.
Joining MabDesign allows us to connect with more biopharma innovators across France and beyond, building deeper relationships in one of the most vibrant and growing hubs for biotherapeutics in Europe.
“We’re thrilled to become a part of MabDesign’s trusted network. France has always been a dynamic region for science and innovation, and this partnership will help us support even more researchers looking to advance biologics discovery and development.”
— Hafid Kora, Regional Account Manager France, Sphere Bio
Together with the MabDesign community, we’re championing bold ideas and smarter science. If you’re attending an upcoming MabDesign event—or just curious about what’s possible with single-cell microfluidics—we’d love to connect.
Let’s accelerate the future of biologics, together.
Learn more about MabDesgin: https://mabdesign.fr
About Sphere Bio
Sphere Bio develops and manufactures single cell analysis and monoclonality assurance systems to enable researchers to find, analyze and isolate the most valuable cells, with ease and speed.
Sphere Bio’s proprietary picodroplet microfluidic platforms are designed specifically for single-cell screening and isolation, allowing users to encapsulate and analyze single cells within a picodroplet, while maintaining viability. Harnessing this technology, the Company’s range of novel microfluidic tools facilitate leading-edge research and accelerate biotherapeutic discovery and development, cell therapy, and synthetic biology workflows, streamlining the journey of discovery in labs, globally.
Sphere Bio is based at Granta Park in Cambridgeshire (UK). The Company has also internationalized its business via a global network of distributors.
For more information contact:
